Auriga Reiterates a 'Buy' on Exact Sciences (EXAS); Raising PT After Q4 Review; Timelines on Track
Tweet
Share
E-mailGet Alerts EXAS Hot Sheet
Price: $104.91 --0%
Rating Summary:
8 Buy, 27 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Rating Summary:
8 Buy, 27 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Join SI Premium – FREE
Auriga reiterates a 'Buy' on Exact Sciences (NASDAQ: EXAS) price target raised from $10 to $13.
Auriga analyst said, "Exact Sciences reported 4Q11 results of $1.0MM/$(0.18). Given EXAS is a development stage company, earnings are not as important as clinical milestones and timelines. Enrollment trends in EXAS' ongoing 10,000+ patient trial remain on track, and the company expects to add 20 new clinical sites in 1Q12 . Enrollment should be completed in 3Q12, with results possible in early 4Q12 (these timelines could prove conservative). Overall, EXAS continues to make steady progress on what could potentially be a game-changer in colorectal cancer screening. EXAS is well funded, and all key development timelines remain on track."
For an analyst ratings summary and ratings history on Exact Sciences click here. For more ratings news on Exact Sciences click here.
Shares of Exact Sciences closed at $9.19 yesterday.
Auriga analyst said, "Exact Sciences reported 4Q11 results of $1.0MM/$(0.18). Given EXAS is a development stage company, earnings are not as important as clinical milestones and timelines. Enrollment trends in EXAS' ongoing 10,000+ patient trial remain on track, and the company expects to add 20 new clinical sites in 1Q12 . Enrollment should be completed in 3Q12, with results possible in early 4Q12 (these timelines could prove conservative). Overall, EXAS continues to make steady progress on what could potentially be a game-changer in colorectal cancer screening. EXAS is well funded, and all key development timelines remain on track."
For an analyst ratings summary and ratings history on Exact Sciences click here. For more ratings news on Exact Sciences click here.
Shares of Exact Sciences closed at $9.19 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- JD.com (JD) Reiterated at Buy by Benchmark Amid Earnings Recovery
- Newton Golf Company (NWTG) Reports Q2 Loss of $0.49
- Freedom Broker Upgrades Lifeway Foods (LWAY) to Buy
Create E-mail Alert Related Categories
Analyst Comments, Analyst EPS View, Analyst PT ChangeRelated Entities
Auriga, EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
